Skip to main content Back to Top


Isocarboxazid Tablets

Products Affected - Description

    • Marplan oral tablet, Validus Pharmaceuticals, 10 mg, bottle, 100 count, NDC 30698-0032-01

Reason for the Shortage

    • Validus has Marplan tablets on shortage due to manufacturing delays. They are in the process of transferring manufacturing sites in the US.

Available Products

    • There are no presentations available

Estimated Resupply Dates

    • Validus has Marplan on long-term back order and the company cannot estimate a release date.

Implications for Patient Care

    • FDA is allowing Validus to temporarily import Marplan from Denmark. This version of Marplan is manufactured by MediLink. The labeling is in Danish. The tablets from Denmark are pink while the tablets from the US are peach. Further descriptors and ordering information can be found at


Updated September 17, 2019 by Leslie Jensen, PharmD, Drug Information Specialist. Created April 11, 2018 by Michelle Wheeler, PharmD, Drug Information Specialist. © 2019, Drug Information Service, University of Utah, Salt Lake City, UT.


This information is provided through the support of Vizient to ASHP solely as a service to its members, which shall not use this information for their further commercial use. The content was prepared by the Drug Information Center of University of Utah. Vizient, ASHP, and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, which respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither Vizient, ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this bulletin. Neither Vizient, ASHP nor University of Utah endorses or recommends the use of any drug.

« Back to Drug Shortage Product Bulletins